Article

A Special Report on the Chitosan-based Hemostatic Dressing: Experience in Current Combat Operations

Madigan Army Medical Center, Tacoma, Washington, United States
The Journal of trauma (Impact Factor: 2.96). 04/2006; 60(3):655-8. DOI: 10.1097/01.ta.0000199392.91772.44
Source: PubMed

ABSTRACT

Hemorrhage remains a leading cause of death in both civilian and military trauma patients. The HemCon chitosan-based hemostatic dressing is approved by the US Food and Drug Administration (FDA) for hemorrhage control. Animal data have shown the HemCon dressing to reduce hemorrhage and improve survival. The purpose of this article is to report preliminary results of the hemostatic efficacy of the HemCon dressing used in the prehospital setting on combat casualties.
A request for case information on use of HemCon dressings in Operation Iraqi Freedom and Operation Enduring Freedom was sent to deployed Special Forces combat medics, physicians, and physician assistants.
Sixty-eight uses of the HemCon dressing were reported and reviewed by two US Army physicians. Four of the 68 cases were determined duplicative resulting in a total of 64 combat uses. Dressings were utilized externally on the chest, groin, buttock, and abdomen in 25 cases; on extremities in 35 cases; and on neck or facial wounds in 4 cases. In 66% of cases, dressings were utilized following gauze failure and were 100% successful. In 62 (97%) of the cases, the use of the HemCon dressing resulted in cessation of bleeding or improvement in hemostasis. There were two reported dressing failures that occurred with blind application of bandages up into large cavitational injuries. Dressings were reported to be most useful on areas where tourniquets could not be applied to control bleeding. The dressings were reported to be most difficult to use in extremity injuries where they could not be placed easily onto or into the wounds. No complications or adverse events were reported.
This report on the field use of the HemCon dressing by medics suggests that it is a useful hemostatic dressing for prehospital combat casualties and supports further study to confirm efficacy.

Download full-text

Full-text

Available from: Ian Wedmore
  • Source
    • "The degradation products of chitosan are N-acetyl-glucosamine and glucosamine, natural constituents of the human body, and thus bioabsorbable[122,123]. Chitosan has shown good biocompatibility[124], and was approved by the FDA for use in wound dressings[125]. All these distinct advantages together indicate chitosan is one of the most remarkable candidates for cell therapy applications. However, similar to other biomaterials, in most cases, the requirements for cell therapy applications cannot be fulfilled by chitosan alone. "

    Preview · Article · Jan 2016 · Marine Drugs
  • Source
    • "Ces pansements se révélaient particulièrement utiles là où un garrot ne pouvait être posé . Les blessures étaient causées par des IED ( Improvised Explosive Device ) , des fragments ( éclats indirects ) et des blessures par arme à feu ( Wedmore I et al , J Trauma 2006 ) . "
    [Show description] [Hide description]
    DESCRIPTION: Hémorragies du post-partum: essai croisé de non-infériorité randomisé en cluster, pragmatique, multicentrique, comparant le pansement hémostatique au chitosan Celox versus le ballon de Bakri dans les saignements résistant au sulprostone (HeLoHPP) auteurs: Philippe Guillermin, Claude Gindrey, Patrick Gérardin
    Full-text · Research · Sep 2015
  • Source
    • "Chitosan has a positive charge and attracts red blood cells (RBC) and platelets, which are negatively charged through ionic interaction; thus, a strong seal is formed at the wound site. [25] This supportive, primary seal allows the body to activate its coagulation pathway effectively, initially forming organized platelets. Therefore, HDDs are designed to maintain this seal and serve as a frontline support structure as the platelets and red blood cells continue to aggregate until hemostasis is achieved [23] [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Dental extractions in heart surgery patients treated with artificial mechanical heart valves under anticoagulant oral therapy can be difficult as these patients present a significant risk for postoperative hemorrhagic complications. This study was performed to evaluate the use of Platelet Rich Fibrin (PRF) and Hemcon dental dressing (HDD) in cardiac patients taking Warfarin following dental extraction. Methods 20 patients were involved in this study with an age range of 36–62 years. Patients having an International Normalized Ratio (INR) >3.5 were excluded. Extraction was performed under local anesthesia and as atraumatic as possible. Patients were allocated equally in two groups; group A: where PRF was inserted into the extraction socket, while group B: the extraction socket was packed by HDD. Results Complete hemostasis was achieved in all cases with no delayed bleeding. Patients in group A showed minimal pain and accelerated healing, while those in group B showed extreme to moderate pain on the first few days following extraction and retarded healing. Four patients developed alveolar osteitis. Conclusions PRF has good antihemorrhagic properties and increases tissue healing and wound closure, thus allowing for a quick recovery without significant painful events. HDD has excellent hemostatic properties and can be used safely in such patients but with small amounts.
    Full-text · Article · Aug 2014
Show more